JPS5892620A - インタ−フエロン安定配合組成物 - Google Patents
インタ−フエロン安定配合組成物Info
- Publication number
- JPS5892620A JPS5892620A JP56191251A JP19125181A JPS5892620A JP S5892620 A JPS5892620 A JP S5892620A JP 56191251 A JP56191251 A JP 56191251A JP 19125181 A JP19125181 A JP 19125181A JP S5892620 A JPS5892620 A JP S5892620A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- items
- interferon
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010050904 Interferons Proteins 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 102000014150 Interferons Human genes 0.000 title claims abstract description 39
- 229940079322 interferon Drugs 0.000 title claims abstract description 38
- 230000002378 acidificating effect Effects 0.000 claims abstract description 13
- 235000000346 sugar Nutrition 0.000 claims abstract description 13
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003381 stabilizer Substances 0.000 claims abstract description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 4
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims abstract description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims abstract description 3
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims abstract description 3
- 229940097043 glucuronic acid Drugs 0.000 claims abstract description 3
- 150000007524 organic acids Chemical class 0.000 claims abstract description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 2
- 210000000214 mouth Anatomy 0.000 claims abstract 2
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 2
- 239000011593 sulfur Substances 0.000 claims abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 238000007915 intraurethral administration Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-KKQCNMDGSA-N D-gulonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-KKQCNMDGSA-N 0.000 claims description 2
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 abstract description 2
- 239000006172 buffering agent Substances 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 abstract 1
- 210000000664 rectum Anatomy 0.000 abstract 1
- 210000003708 urethra Anatomy 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 239000000499 gel Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000015927 pasta Nutrition 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- REYLLNRLWCBKCM-YFKPBYRVSA-N (2s)-2-acetamido-4-sulfanylbutanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCS REYLLNRLWCBKCM-YFKPBYRVSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- YODZTKMDCQEPHD-UHFFFAOYSA-N thiodiglycol Chemical compound OCCSCCO YODZTKMDCQEPHD-UHFFFAOYSA-N 0.000 description 1
- 229950006389 thiodiglycol Drugs 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56191251A JPS5892620A (ja) | 1981-11-28 | 1981-11-28 | インタ−フエロン安定配合組成物 |
| EP82306319A EP0080879B1 (en) | 1981-11-28 | 1982-11-26 | Pharmaceutical composition containing interferon in stable state |
| DE8282306319T DE3273597D1 (en) | 1981-11-28 | 1982-11-26 | Pharmaceutical composition containing interferon in stable state |
| US06/568,033 US4675184A (en) | 1981-11-28 | 1984-01-04 | Pharmaceutical composition containing interferon in stable state |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56191251A JPS5892620A (ja) | 1981-11-28 | 1981-11-28 | インタ−フエロン安定配合組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5892620A true JPS5892620A (ja) | 1983-06-02 |
| JPH038323B2 JPH038323B2 (cg-RX-API-DMAC7.html) | 1991-02-05 |
Family
ID=16271416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56191251A Granted JPS5892620A (ja) | 1981-11-28 | 1981-11-28 | インタ−フエロン安定配合組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5892620A (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63146827A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
| WO1993001825A1 (fr) * | 1991-07-19 | 1993-02-04 | Otsuka Pharmaceutical Co., Ltd. | Medicament antitumoral |
| JPH07119501B2 (ja) * | 1988-12-28 | 1995-12-20 | 敏郎 鈴木 | コンクリート支柱材 |
| JP2003533466A (ja) * | 2000-05-18 | 2003-11-11 | ツェンタリス アクチエンゲゼルシャフト | ペプチドの薬剤適用形、その製造法及び使用 |
-
1981
- 1981-11-28 JP JP56191251A patent/JPS5892620A/ja active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63146827A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
| JPH07119501B2 (ja) * | 1988-12-28 | 1995-12-20 | 敏郎 鈴木 | コンクリート支柱材 |
| WO1993001825A1 (fr) * | 1991-07-19 | 1993-02-04 | Otsuka Pharmaceutical Co., Ltd. | Medicament antitumoral |
| JP2003533466A (ja) * | 2000-05-18 | 2003-11-11 | ツェンタリス アクチエンゲゼルシャフト | ペプチドの薬剤適用形、その製造法及び使用 |
| JP2011213733A (ja) * | 2000-05-18 | 2011-10-27 | Aeterna Zentaris Gmbh | ペプチドの薬剤適用形、その製造法及び使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH038323B2 (cg-RX-API-DMAC7.html) | 1991-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5892619A (ja) | インタ−フエロンを安定に配合した組成物 | |
| EP0080879B1 (en) | Pharmaceutical composition containing interferon in stable state | |
| US5236707A (en) | Stabilization of human interferon | |
| DE3723781C2 (de) | Verwendung von Polyoxyäthylensorbitanestern einer aliphatischen Säure zur Stabilisierung von G-CSF (Granulocyten-Koloniestimulierender-Faktor) | |
| US4911908A (en) | Interferon administration vehicles | |
| EP0374257B1 (en) | STABLE INTERFERON $g(b) COMPOSITION | |
| HU225494B1 (en) | Stable, aqueous alfa interferon solution formulations | |
| JPS5910598A (ja) | 安定なインタ−フエロンβ組成物およびインタ−フエロンβの安定化方法 | |
| AU601712B2 (en) | Stabilised formulations of alpha-interferon | |
| JPH04502017A (ja) | 小ペプチド類の安定化水系調剤 | |
| EP0809512B1 (en) | Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin | |
| PT759775E (pt) | Formulacoes liquidas de ifn-b | |
| JPS5892620A (ja) | インタ−フエロン安定配合組成物 | |
| Kulics et al. | Regulation of synthesis of complement protein C4 in human fibroblasts: cell-and gene-specific effects of cytokines and lipopolysaccharide | |
| JPH0776527A (ja) | 半固形製剤とその製造方法 | |
| JPS5892622A (ja) | インタ−フエロン安定配合製剤 | |
| JPH0780760B2 (ja) | 安定化されたフエニレフリン系液剤 | |
| JPS58167520A (ja) | インタ−フエロン安定配合製剤 | |
| JPS5892621A (ja) | インタ−フエロンを安定に配合した製剤 | |
| CN115919683A (zh) | 一种透明组合物及其制备方法和应用 | |
| JPH08104642A (ja) | ヒアルロン酸ナトリウム注射液用安定化組成物 | |
| JPS62153226A (ja) | インタ−フエロンβ組成物 | |
| JPH069430A (ja) | 安定なリゾチーム配合点眼剤 | |
| CN100502943C (zh) | 一种重组人促红细胞生成素的药物注射剂 | |
| KR100671449B1 (ko) | 송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물 |